

euroPLX



Business Developer

Vol. 13 #8/9 | August/September | 2017

## Company News: Acquisitions, Licensing, Co-Distribution, Name Changes

\* Acquisition: **Alvogen** has signed a definitive agreement to acquire **Omega Bittner**, a Russia-based pharmaceutical firm owned by **Perrigo Company plc**. Working with well-established and recognized brands in Russia including Lactacyd<sup>TM</sup>, Aflubin<sup>TM</sup> and Paranit<sup>TM</sup>, the firm focuses on a targeted portfolio of over-the-counter drugs in categories such as women's healthcare and cough & cold. The transaction is expected to close by the end of Q3 2017. 15 Aug 2017 ([www.alvogen.com](http://www.alvogen.com))

\* Acquisition: **AstraZeneca** has entered into an agreement with **Aspen Global Incorporated (AGI)**, part of the **Aspen Group**, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest. AGI will now acquire the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines for an upfront consideration of \$555 million. Additionally, AGI will pay AstraZeneca up to \$211 million in performance-related milestones based on sales and gross margin during the period from 1 September 2017 to 30 November 2019. AstraZeneca will continue to manufacture and supply the medicines to AGI dur-

ing a transition period of up to five years. 14 Sep 2017 ([www.astrazeneca.com](http://www.astrazeneca.com))

\* Distribution: **Basilea Pharmaceutica International Ltd.** has entered into a distribution agreement with **Cardiome Pharma Corp.** for Basilea's antibiotic Zevtera<sup>®</sup>/Mabelio<sup>®</sup> (ceftobiprole) in Europe (excluding Nordic countries) and Israel. Under the terms of the agreement, Cardiome is granted an exclusive license to commercialize ceftobiprole in more than 30 countries in Europe and in Israel. Basilea will receive an

cal company. The total consideration for the transaction was approximately \$625 million. The transaction was financed through a combination of cash on hand and debt. 27 Jul 2017 ([www.baxter.com](http://www.baxter.com))

\* Distribution: **Beximco Pharmaceuticals Limited**, a Bangladeshi manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. 17

on enhancing the innate immune response for treating cancer. 7 Sep 2017 ([www.bms.com](http://www.bms.com))

\* Name change: **M Pharmaceutical Inc.** announced that to better align with its expertise in the healthcare field, it is changing the name and branding of its wholly owned subsidiary **MPharmaceutical USA** branding to **Callitas Therapeutics Inc.** The name of the parent company remains as it is for now. 1 Aug 2017 ([callitas.com/](http://callitas.com/))

\* Acquisition: **Crescita Therapeutics Inc.**, a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products, today announced that its wholly owned subsidiary, **INTEGA Skin Sciences** has acquired the Alyria skincare line of products from **Sanofi Consumer Health Inc.** Crescita purchased Alyria for cash consideration of \$1.7 million, consisting of a combination of fixed cash installments, of which \$0.8 million will be paid in 2017, as well as a royalty agreement based on a threshold of annual net sales of Alyria over a nine-year period starting in 2020. 8 Aug 2017 ([www.crescitatherapeutics.com](http://www.crescitatherapeutics.com))

\* Distribution: **Easton Pharmaceuticals Inc.** has executed and closed a sub-distribution agreement with **Gedeon Richter Plc** and its Mexican subsidiary company

### Advertisement - Position Offered

**DSM Sinochem Netherlands** is expanding its activities and is therefore looking for the following position in its business unit of drug products:

#### Global Business & In-Licensing Manager

Detailed position profiles and online application available at [www.dsm-sinochem.com](http://www.dsm-sinochem.com) or LinkedIn.com

Please send your application with resume to [hrdsonl@dsm-sinochem.com](mailto:hrdsonl@dsm-sinochem.com)

[This is a free service to a euroPLX Community Member.](#)

upfront payment of CHF 5 million and is eligible for additional payments upon achievement of pre-specified regulatory and commercial milestones. 12 Sep 2017 ([www.basileapharma.com](http://www.basileapharma.com))

\* Acquisition: **Baxter International Inc.** completed the acquisition of **Clarix Injectables Limited**, a global generic injectables pharmaceuti-

cal company. 17 Sep 2017 ([www.beximco-pharma.com](http://www.beximco-pharma.com))

\* Acquisition: **Bristol-Myers Squibb Company** has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM's preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused

**Gedeon Richter S.A.P.I de C.V.** for the product "AmnioSense", a patented amniotic fluid leak test that will be marketed in two presentations to capture maximum market. It is a unique Point-of-Care diagnostic panty liner for women in late-stage pregnancy able to distinguish between urine and amniotic fluid (breaking of water). 10 Aug 2017 ([www.eastonpharmaceuticalsinc.com](http://www.eastonpharmaceuticalsinc.com))

\* Acquisition: **Eurofins Scientific** has signed an agreement to acquire **EAG Laboratories**, a leading global scientific services company providing analytical testing and consulting solutions to a diverse and demanding set of end markets, from **Odyssey Investment Partners**. The transaction is expected to close in the next few months. 18 Sep 2017 ([www.eurofins.com](http://www.eurofins.com))

\* Acquisition: **Evotec AG** has successfully completed the acquisition of **Aptuit**. Evotec paid a total consideration of approx. \$ 300 m (approx. EUR 256 m; EUR/\$ fx rate of 1.17) in cash for the acquisition of Aptuit from Welsh, Carson, Anderson & Stowe, a private equity firm. 16 Aug 2017 ([www.evotec.com](http://www.evotec.com))

\* Co-Promotion: **Helsinn Healthcare SA's** US subsidiary **Helsinn Therapeutics (US), Inc.**, has signed a co-promotion agreement with Novartis for Zykadia®, an approved treatment for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected with an FDA approved test. 5 Sep 2017 ([www.helsinn.com](http://www.helsinn.com))

\* Licensing: **Hikma Pharmaceuticals PLC's** wholly owned subsidiary **Hikma Pharmaceuticals LLC** has agreed to expand its licensing and distribution agreement with **Takeda Pharmaceutical Company Limited**, adding new products to its portfolio in the Middle East and North Africa (MENA). 17 Aug 2017 ([www.hikma.com](http://www.hikma.com))

\* Name change: **KaloBios Pharma-**

**ceuticals, Inc.** has changed its name to **Humanigen Inc.** effective immediately. 7 Aug 2017 ([www.humanigen.com](http://www.humanigen.com))

\* Acquisition: **Merck**, known as **MSD** outside the United States and Canada, will acquire **Rigotec**. Rigotec's lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors. Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of €115 million to Rigotec's shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to €349 million. The transaction is subject to certain closing conditions. 6 Sep 2017 ([www.merck.com](http://www.merck.com))

\* Name Change: **MT Pharma America, Inc.** announced the change of its corporate name to **Mitsubishi Tanabe Pharma America, Inc. (MTPA)**, effective immediately. 1 Aug 2017 ([www.mt-pharma.co.jp/e/](http://www.mt-pharma.co.jp/e/))

\* Divestment: **Moberg Pharma AB** has completed the divestment of the Fiber Choice® brand to Caret Pharma LLC. for a total consideration of \$6.7 million plus the inventory value. The divestment results in a capital gain of circa \$1.6 million. 28 Aug 2017 ([www.mobergderma.se](http://www.mobergderma.se))

\* Distribution: The **Mundipharma** network of independent associated companies has entered into an exclusive distribution agreement with **Janssen Pharmaceutica NV** for primary care type 2 diabetes medicines Invokana® (canagliflozin) and Vokanamet® (a fixed-dose combination therapy of canagliflozin and metformin). The agreement includes all countries in the European Economic Area (EEA) and Switzerland where the products have obtained price and reimbursement approvals. 4 Sep

2017 ([www.mundipharma.co.uk](http://www.mundipharma.co.uk))

\* Distribution: **Orexigen Therapeutics, Inc.'s** wholly owned subsidiary, **Orexigen Therapeutics Ireland Ltd.**, and **Cheplapharm Arzneimittel GmbH** have executed a distributorship agreement covering Germany, France and Austria for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release). Under the terms of the agreement, Cheplapharm will be responsible for all commercialization activity and expenses. Orexigen will supply Mysimba to Cheplapharm for a negotiated transfer price. Cheplapharm Arzneimittel GmbH is a pharmaceutical company headquartered in Greifswald, Germany with subsidiaries in France and the U.S. that holds more than 150 marketing authorizations in more than 100 countries worldwide. 7 Aug 2017 ([www.orexigen.com](http://www.orexigen.com))

\* Acquisition: **Sanofi** has completed the acquisition of **Protein Sciences**, a vaccines biotechnology company based in Meriden, Connecticut in the United States. Through the acquisition, Sanofi Pasteur, the vaccines global business unit of Sanofi, adds a promising product to its influenza vaccine portfolio: Flublok® (Influenza Vaccine), the only recombinant protein-based influenza vaccine approved by the US Food and Drug Administration (FDA). 28 Aug 2017 ([www.sanofi.com](http://www.sanofi.com))

\* Licensing: **Taiho Pharmaceutical Co., Ltd.** has entered into an option and license agreement with **Arcus Biosciences**, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, as of September 19th 2017. Based on the terms of the agreement, Taiho will provide a \$35mm payment to Arcus. In return for the payment, Taiho will receive an option to in-license the development and commercialization rights of product candidates in Arcus's portfolio in Japan and

certain other territories in Asia (excluding China). For any product candidate for which Taiho exercises a license, Taiho will need to provide option payments in development, regulatory and commercial milestones per molecule. Taiho will also need to pay royalties on the net sales of each product candidate that Taiho commercializes in its regions. 20 Sep 2017 ([www.taiho.co.jp/english/](http://www.taiho.co.jp/english/))

\* Acquisition: **Teva Pharmaceutical Industries Ltd.** has entered into two agreements to sell the remaining assets of its specialty global women's health business for \$1.38 billion. Proceeds from these sales, combined with proceeds from the recently announced sale of PARAGARD® total \$2.48 billion and will be used by Teva to progress repayment of term loan debt. Teva has also entered into a definitive agreement under which Foundation Consumer Healthcare will acquire Plan B One-Step® and Teva's value brands of emergency contraception, Take Action®, Aftera®, and Next Choice One Dose® for \$675 million in cash. 18 Sep 2017 ([www.tevapharm.com](http://www.tevapharm.com))

## BD People on the Move

\* C4 Therapeutics: **Michael Kim, Ph.D.**, who held Corporate Strategy and Business Development positions at Alkermes, Vertex Pharmaceuticals and FORUM Pharmaceuticals has been appointed as Vice President of Business Development. (Press Release 11 Aug 2017)

\* Fate Therapeutics, Inc.: **Jim Beitel, M.B.A.**, previously Vice President of Corporate Development and Operations at Avanir Pharmaceuticals, has been appointed as Senior Vice President, Corporate Development. (Press Release 14 Sep 2017)

\* Helm France Sarl: **Friederike Elissalt**, who served until most recently as Licensing Manager for Ethypharm, has been appointed as Head of Business Development. (Pers Comm 9 Aug 2017)

\* J. Uriach & Cia.: **Natalia Kassai**, who has been Business Development Manager, left the

company. (Pers Comm 19 Sep 2017)

\* Jounce Therapeutics, Inc.: **Hugh Cole**, who most recently served as chief business officer for ARIAD Pharmaceuticals, has been appointed as chief business officer and head of corporate development. (Press Release 15 Aug 2017)

\* Rafarm Pharmaceuticals S.A.: **Dimitris Georgiou**, who has been Business Development Manager, left the company. (Pers Comm 19 Sep 2017)

\* Theravance Biopharma, Inc.: **Shehnaaz Suliman, MD**, who most recently held the position of Vice President Roche Partnering, has

been appointed to the position of Senior Vice President, Corporate Development and Strategy. (Press Release 31 Jul 2017)

## Insanely Effective Pharma Partnering

euroPLX is the world's most often held partnering conference for the pharma and biopharma industries.

Because of results delivered. Year-round.

Join the 65th International Partnering Conference for Pharma Business Development\*

\*euroPLX 65 London (UK)

November 27 + 28, 2017, Sofitel London Heathrow

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Each euroPLX Conference's actual collaboration interests are summarised and displayed on [www.europlx.com](http://www.europlx.com) as an hourly updated **Dynamic Partnering Focus**, as soon as sufficient data are submitted by registrants.

 **euroPLX**  
by RauCon

[www.europlx.com](http://www.europlx.com)  
[meetyou@europlx.com](mailto:meetyou@europlx.com)  
ph. ++49 (6221) 426296-0

The Original since 1995.  
Often copied. Never equaled.

Register online: [www.europlx.com](http://www.europlx.com)

